Literature DB >> 2893200

Subcutaneous apomorphine in parkinsonian on-off oscillations.

C M Stibe1, A J Lees, P A Kempster, G M Stern.   

Abstract

Subcutaneous apomorphine, a dopamine agonist, was given by continuous infusion during the day or by repeated injections to 19 patients with Parkinson's disease disabled by severe on-off fluctuations. All patients were also given domperidone. The 11 patients treated by infusion showed marked and sustained improvement, and their mean duration of daily off periods over a period of 15 months fell by 6.3 h; similar results were obtained in 8 patients with less severe disabilities who were given repeated apomorphine injections. The therapeutic response to apomorphine was similar to that seen with intravenous levodopa; in patients treated by infusion the mean daily levodopa dose was reduced by 209 mg. These results confirm that during off periods dopamine receptors remain responsive to stimulation and provide evidence of a new, effective, and well-tolerated treatment for the most disabling complication of long-term levodopa therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893200     DOI: 10.1016/s0140-6736(88)91193-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  56 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.

Authors:  M Merello; Z Pirtosek; S Bishop; A J Lees
Journal:  Clin Auton Res       Date:  1992-08       Impact factor: 4.435

4.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

5.  Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.

Authors:  K Ray-Chaudhuri; R J Abbott; P A Millac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

6.  Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease.

Authors:  B Kleedorfer; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 7.  The modern management of Parkinson's disease.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

Review 8.  High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review.

Authors:  R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 9.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

10.  Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.

Authors:  T R K Varma; S H Fox; P R Eldridge; P Littlechild; P Byrne; A Forster; A Marshall; H Cameron; K McIver; N Fletcher; M Steiger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.